Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

Background BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expression profiles, and preclinical evidence suggests t...

Full description

Bibliographic Details
Main Authors: Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino, Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Yoshito Komatsu, Eiji Shinozaki, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/6/e000590.full

Internet

https://esmoopen.bmj.com/content/4/6/e000590.full

Similar Items